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1.  Aim, scope and audience of the guidelines 
These guidelines make recommendations for the investigation and management of 
patients within the United Kingdom who present with features compatible with a 
diagnosis of atypical haemolytic uraemic syndrome (aHUS). The guidelines are 
intended for use by healthcare professionals involved in the management of such 
patients.  The recommendations in the guidelines are in keeping with other guidelines 
recently published by the European Paediatric Study Group for HUS (Ariceta, et al 
2008) and the Consensus Study Group for liver-kidney transplantation in aHUS 
(Saland, et al 2008). The GRADE system (http://www.gradeworkinggroup.org) has 
been used to classify the strength of recommendations (strong or weak) and the 
quality of evidence (high, moderate, low and very low) (Guyatt, et al 2008). 
2. Classification, nomenclature and background 
Haemolytic Uraemic Syndrome (HUS) is a disease characterised by the triad of acute 
renal failure, thrombocytopenia and microangiopathic haemolytic anaemia (Coombs’ 
test negative). The demonstration of a role for enterohaemorrhagic Escherichia coli 
and verotoxin (shiga-like toxin) in D+HUS (Karmali, et al 1983) confirmed the  
differentiation between diarrhoea-associated  and non-diarrhoeal forms (D-) forms 
(Barratt, et al 1987).  The D- form subsequently also became known as atypical HUS 
(aHUS). In a small number of patients the disease was also shown to be familial 
(Kaplan, et al 1975) and/or recurrent (Kaplan 1977).  
Our increased understanding of the molecular mechanisms responsible for both HUS 
and thrombotic thrombocytopenic purpura (TTP) has lead to the need to re-examine 
the classification of these diseases. A recent publication from the European Paediatric 
Research Group for HUS has suggested that a new classification based on aetiology  
be adopted (Besbas, et al 2006). Table 1 shows this new classification, those diseases 
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which might currently be considered under the heading of aHUS are highlighted. The 
term “aHUS” will be used throughout the rest of these guidelines and the forms which 
comprise this group are the focus of this document. 
2.1 Infection induced HUS  
Infection-induced HUS includes shiga and shiga-like (toxin)-producing bacteria 
(classically associated with D+ HUS) and Streptococcus Pneumoniae. Typically 
D+HUS is triggered by enterohaemorrhagic Escherichia coli, manifests as an acute 
self-limiting disease and  >90% of childhood cases recover independent renal function 
spontaneously.  Invasive Streptococcus pneumoniae produce neuraminidase that 
cleaves sialic acid residues from various glycoproteins, and on red cells surfaces 
exposes the Thomsen-Freidenreich antigen (T-antigen). Desialation is thought to 
predispose to a thrombotic microangiopathy (Klein, et al 1977).  
2.2 Disorders of complement regulation 
Disorders of complement regulation includes mutations and copy number variation in 
the genes encoding factor H (CFH), membrane cofactor protein (MCP), factor I 
(CFI),  factor B (CFB), C3 (C3) and factor H related proteins 1-5 (CFHR1-5). 
In ~30% of patients mutations  will be found in the gene encoding the soluble 
complement regulator factor H (Saunders, et al 2006).  
Autoantibodies against factor H have been reported in ~10% of aHUS patients 
(Dragon-Durey, et al 2005, Jozsi, et al 2007) and are associated with deficiency of 
factor H related protein 1(Jozsi, et al 2007) .  
In ~10% of patients mutations are found in the widely expressed transmembrane 
regulator membrane cofactor protein  (Richards, et al 2007).  
In another 10% mutations are found in the serine protease factor I which is 
responsible for cleaving complement convertases with the aid of cofactors such as 
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factor H and MCP. Mutations in factor I that affect both secretion and function have 
been reported (Caprioli, et al 2006, Fremeaux-Bacchi, et al 2004, Kavanagh, et al 
2005).  
Activating mutations in complement factor B and C3 have also recently been reported 
in a small number of patients (Fremeaux-Bacchi, et al 2008, Goicoechea de Jorge, et 
al 2007).  A hybrid complement gene which encodes a protein identical to a mutant 
form of factor H has also been described (Venables, et al 2006).  The penetrance of 
mutations in these genes is ~50% and it has been shown that a variety of factors 
including copy number of other complement genes (Zipfel, et al 2007) and 
susceptibility haplotypes in factor H and MCP (Caprioli, et al 2003, Esparza-Gordillo, 
et al 2005) are responsible. It has also been shown that mutations in more than one 
complement gene can influence the predisposition to developing HUS (Esparza-
Gordillo, et al 2006).  
2.3 ADAMTS13 Deficiency 
On rare occasions, patients presenting with the clinical phenotype of  aHUS have a 
profound deficiency of ADAMTS13, either due to a congenital ADAMTS13 defect 
(eg. in young children) or acquired antibody to ADAMTS1. These patients are better 
described as having TTP and should  be managed according to the “Guidelines on the 
Diagnosis and Management of the Thrombotic Microangiopathic Haemolytic 
Anaemias” (Allford, et al 2003) 
2.4 Disorders of defective cobalamine metabolism  
Disorders of intracellular cobalamine metabolism, usually Cobalamin C disease, 
predispose to a thrombotic microangiopathy (cblC) (Geraghty, et al 1992). This is 
characterised by methylmalonic aciduria and homocystinuria,. HUS with cblC has 
also been associated with a factor H mutation (Guigonis, et al 2005)  
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2.5 Quinine induced thrombotic microangiopathy  
Quinine induced thrombotic microangiopathy is associated with antibodies against 
glycoproteins on platelets.   
2.6. Other diseases associated with a thrombotic microangiopathy. 
Diseases associated with a thrombotic microangiopathy where the aetiology is not so 
well defined includes HIV, malignancy, drugs (including cytotoxics, calcineurin 
inhibitors, oral contraceptives  and antiplatelet agents) (Dlott, et al 2004),  pregnancy, 
SLE and  antiphospholipid antibody syndrome.  
3. Demography of aHUS. 
 aHUS is a rare disease (incidence ~ 2 per million population per year) that affects all 
ages but primarily children and young adults. The incidence of aHUS in children is 
approximately 5 percent that of typical HUS. Updated national data on paediatric 
HUS established for some European countries (France, Germany, Austria and Italy) 
enable an estimated prevalence of aHUS of 7 per million children in the whole of the 
European Community.  
4. Investigations in patients presenting with aHUS 
4.1 Measurement and interpretation of serum complement components.  
Blood should be taken for the measurement of C3, C4, factor H and factor I 
concentration, and for antibodies against complement components (see 4.4) before 
either plasma exchange or plasma infusions are commenced. C4 levels are in most 
cases normal. C3 levels can be either normal or low in patients with a mutation in 
CFH, CFI and MCP. The percentage of patients who have a normal C3 level in the 
presence of such a change ranges from 50% for CFH to 30% for CFI and 70% for 
MCP (Caprioli, et al 2006, Kavanagh, et al 2006).  ~10% of patients who do not have 
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an identified mutation or autoantibodies to factor H will have a low C3 level 
suggesting that other as of yet unidentified complement components are involved.   
Factor H and factor I concentrations will be normal in those patients with a mutation 
that does not affect secretion of the mutant protein. This includes both missense 
mutations and deletions (Saunders, et al 2007, Saunders, et al 2006). Factor H and 
factor I concentrations are lower in neonates (de Paula, et al 2003) and this has to be 
taken into account when interpreting results in this age group.  There is also a large 
variation in factor H concentrations in normal adults and use of “normal ranges” to 
interpret individual results must be cautious. The majority of factor H mutations that 
result in impaired secretion are heterozygous and one would therefore expect that in 
such individuals the factor H concentration would be ~50% of normal.  However, 
because the population normal range is so large a 50% concentration for an individual 
may still lie within the population normal range.  Of the factor H mutations listed on 
the FH-HUS mutation database (www.fh-hus.org) 37% are associated with a normal 
factor H level and 22% a low level.   For the factor I mutations listed on the same 
database 42% are associated with a low factor I level and 25% a normal level. As for 
factor H the majority of those mutations in factor I that result in impaired secretion 
are heterozygous.  
Recommendation.  In all patients presenting with clinical features compatible with a 
diagnosis of aHUS serum levels of C3, C4, factor H and factor I should be measured 
as the results guide prognosis and transplantation options. (strong, moderate) 
4.2 FACS analysis.  
Because MCP is a transmembrane protein, FACS analysis provides a means to 
quickly screen for mutations that result in decreased expression.  A wide range of 
antibodies are commercially available. Expression of MCP on peripheral blood 
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mononuclear cells (PBMCs) is stable at room temperature for up to 4 days. The time 
from venesection to analysis should be kept within this time. ~70% of  MCP 
mutations are associated  with decreased expression by FACS analysis. The majority 
of these are heterozygous but there are a few rare compound heterozygous and 
homozygous individuals. 
Recommendation.  In all patients presenting with clinical features compatible with a 
diagnosis of aHUS expression of MCP on PBMCs should be assessed using FACS 
analysis in an appropriately accredited laboratory as the results guide prognosis and 
late transplantation options. (strong, moderate) 
4.3 Genetic analysis 
As mentioned previously normal levels or expression of factor H, factor I and MCP 
do not rule out the possibility of a normally expressed but functionally impaired 
mutant. Full genetic analysis is therefore recommended for all patients as the results 
guide prognosis and transplantation options.  
In patients with low serum levels or expression of factor H, factor I and MCP in 
association with nonsense mutations, frameshift mutations, splice site mutations or 
missense mutations affecting critical residues (such as the cysteine residues in factor 
H responsible for forming disulphide bonds) it is probable that the abnormalities 
predispose to the disease.  The interpretation is more difficult when the change is 
novel, has not been examined functionally and occurs in a region where there is no 
known function. 
Mutations have now been described in five complement genes and it is likely that 
further genes will be identified.  At present the turn around time for screening the 
genes for factor H, factor I and MCP alone is several months. For clinicians to be able 
to make timely decisions particularly about treatment, particularly transplantation, this 
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needs to be improved. New sequencing platforms are being introduced which will 
substantially reduce this turn around time. The Northern Molecular Genetics Service 
in Newcastle upon Tyne is the approved UK  Genetics Testing Network  laboratory 
for HUS (www.ukgtn.org). This laboratory has recently installed a Roche FLX 
System Genome Sequencer which allows ultra-rapid high-throughput sequencing. 
With a single read accuracy greater than 99.5% 100 million base pairs can generated 
in an 8 hour run. Platforms such as this will undoubtedly be the method of choice in 
the future for mutation screening in HUS patients. 
Recommendations. Mutation screening of the genes encoding factor H, MCP, factor 
I, factor B and C3 should be undertaken in all patients with aHUS. This includes all 
historic cases who are being considered for transplantation. This should be 
undertaken in appropriately accredited molecular diagnostic laboratories and include 
appropriate techniques to detect copy number variation and hybrid genes.  If 
mutations are found in other genes in the research setting then these should be 
incorporated into the molecular diagnostic portfolio. (strong, moderate) 
4.4 Autoantibody screening 
Between 6-10% of aHUS patients have antibodies which bind to the C terminal region 
of factor H (Dragon-Durey, et al 2005, Jozsi, et al 2007). These can be detected with 
an ELISA using human factor H-coated plates to capture anti-CFH antibodies.  
Recommendations. Autoantibodies against factor H should be sought in all patients 
with end aHUS. This should be undertaken in an appropriately accredited laboratory. 
(strong, moderate) 
4.5 Rare causes of aHUS.  As mentioned previously a thrombotic microangiopathy 
can also be seen in association with malignancy, drugs, HIV infection, pregnancy, 
SLE, antiphospholipid antibody syndrome and Cobalamin C disease. 
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Recommendations. The possibility of these rarer forms of aHUS should be 
considered at presentation and appropriate investigations undertaken. (strong, 
moderate) 
4.6 Measurement and interpretation of ADAMTS13 Activity 
A clinical  diagnosis of aHUS is made when the predominant presenting feature is 
acute renal failure whereas a diagnosis of TTP is made when the predominant 
presenting feature is neurological. However, renal involvement is common in TTP, 
with proteinuria and microscopic haematuria being the most constant findings 
(Kennedy, et al 1980, Ruggenenti and Remuzzi 1990). Renal function is depressed in 
40% to 80% of patients, although severe acute renal failure (which is the hallmark of 
aHUS) is rare (Ruggenenti and Remuzzi 1990). For this reason TTP has been closely 
intertwined with HUS, as evidenced by frequent use of the hybrid term HUS/TTP in 
the literature (Galbusera, et al 1999, Remuzzi, et al 2002a). Measurement of 
ADAMTS 13 activity can help to differentiate between these two clinical diagnoses.  
In TTP two primary mechanisms for deficiency of the ADAMTS13 activity have been 
identified, namely a constitutive deficiency and the presence of a circulating acquired 
inhibitory antibody (Furlan, et al 1998, Tsai and Lian 1998). In aHUS low levels of 
protease activity can be seen  in the absence of either an inherited deficiency or anti-
ADAMTS13 antibodies but both these two abnormalities can also present with a 
clinical phenotype of aHUS (Remuzzi, et al 2002a, Veyradier, et al 2001). It is 
therefore important that specific assays are undertaken to detect these two 
abnormalities in patients with a clinical diagnosis of aHUS in whom the presence of 
low levels of ADAMTS13 protease activity is detected. 
Recommendations.  Measurement of ADAMTS13 activity should be undertaken in 
patients with a clinical diagnosis of aHUS in whom other investigations do not show 
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an underlying abnormality.  If ADAMTS13 activity is found to be low specific assays 
to detect inherited deficiency or anti-ADAMTS13 antibodies should be undertaken. 
(weak, low) 
5. Management of aHUS 
5.1 Plasma exchange/plasma infusion.  
Plasma exchange and/or plasma infusions have become empirical, first line 
management of a patient presenting with the features of aHUS (reviewed in (Barz, et 
al 2002, Kwon, et al 2008, von Baeyer 2002)). However, the information for which 
therapeutic strategy is most appropriate is limited. Plasma exchange is commonly 
undertaken daily using  1-2 plasma volumes per session in adults and 50-100 ml/kg in 
children. Typically plasma exchange is undertaken daily initially, the duration and 
frequency of treatment is then determined by the clinical response. The theoretic 
advantage of plasma exchange over infusion has been emphasised in childhood cases 
in whom the risk of rapid progression to end-stage renal failure is high (Ariceta, et al 
2008). Plasma infusion is undertaken daily initially, but may be dose limited because 
of impaired renal function and hypertension. If it appears successful with reversal of 
the microangiopathic anaemia the dose and frequency may be reduced later to weekly 
or biweekly intervals. However, individual patients respond differently and some 
require daily plasma infusions for long periods. Apart from this and general 
supportive measures there is currently no specific therapy for aHUS. Genotype-
phenotype correlations have helped to explain some of the variation seen in patient 
response.  For instance patients with abnormalities in  soluble regulators such as 
factor H respond better to plasma exchange than  patients with abnormalities in the 
transmembrane regulator MCP (Caprioli, et al 2006) .  
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The clinical outcome for patients who present with aHUS is poor. There is an initial 
25% mortality and 50% of survivors do not recover renal function (Caprioli, et al 
2006). 
Recommendations. All patients presenting with aHUS should be offered a trial of 
plasma exchange and/or plasma infusions. (weak, low) 
5.2 Kidney transplantation.  
Renal transplantation is associated with an overall ~50% rate of HUS recurrence in 
the allograft. The outcome varies according to the underlying genetic abnormality. 
Renal transplantation in patients known to have either a CFH or CFI mutation has a 
very poor outcome  with 80% of patients losing their graft to recurrent disease within 
two years (Bresin, et al 2006). In contrast transplantation in patients with defects in 
only the transmembrane regulator MCP have a good outcome. In this case the 
defective protein is replaced with the transplant and normal situation is restored. 
Information about the outcome of transplantation in patients with C3 and CFB 
mutations is becoming available and suggests that the outcome of renal 
transplantation is also compromised by a significant risk of recurrence. There is, 
however, insufficient data at present to make specific recommendations for this group 
of patients. Likewise information about the outcome of renal transplantation alone in 
those patients known to have anti factor H autoantibodes is limited but does suggest 
again that there is a significant risk of recurrence. However, there is evidence that use 
of plasma exchange in combination with Rituximab can enable a satisfactory outcome 
(Kwon, et al 2008). Thus, there is a need to define the primary genetic defect in 
patients with aHUS, as this information is informative for therapy and disease 
progression.  Live related renal  transplantation alone is associated with the same risk 
of recurrence in the aforementioned groups and also a risk of  the donor developing 
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the disease if they should carry the same mutation as the recipient (Donne, et al 
2002).  
Recommendations. Renal transplantation alone is not recommended in patients 
known to have a factor H or factor I mutation. Patients carrying an MCP mutation, 
but no additional mutation in factor H, factor I, factor B and C3 or an anti-factor H 
autoantibody  can be informed that the risk of recurrence post transplantation  is low. 
Patients known to have a C3 or CFB  mutation should be informed that current 
evidence suggests that there is a significant risk of disease recurrence post 
transplantation. Patients known to have an anti-factor H autoantibody should be 
treated to minimise the antibody titre before proceeding to renal transplantation.  
Living related renal transplantation alone should be avoided in  aHUS. (strong, 
moderate) 
5.3 Liver and combined liver/kidney transplantation.  
Factor H is primarily produced by the liver and liver or combined liver/kidney 
transplantation is therefore a logical treatment for patients known to have a factor H 
mutation. Combined liver/kidney transplantation has been undertaken for those 
patients with a  factor H mutation, and one child with moderate renal damage has 
been treated with an isolated liver graft. This appears logical given that both factor H 
and factor I are produced predominantly by the liver. Whilst the initial experience 
with this was not favourable (Cheong, et al 2004, Remuzzi, et al 2002b, Remuzzi, et 
al 2005) more recent studies have documented a good outcome (Jalanko, et al 2008, 
Saland, et al 2006).  This may be influenced by the use of prophylactic plasma 
exchange immediately prior to surgery and plasma infusion intraoperatively. 
In patients who have stable renal function but disease relapses in spite of plasma 
therapy an isolated orthotopic liver transplant may be considered. 
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Recommendations.  In aHUS patients with a known mutation in either factor H or 
factor I consideration should be given either an isolated liver or  a combined 
liver/kidney transplant as part of an internationally coordinated clinical trial. Within 
the UK an advisory panel should be established to consider all patients prior to 
listing. Within the UK liver transplantation alone or in combination with a kidney 
transplant should only be undertaken in a limited number of centres with appropriate 
expertise. (weak, low) 
 
6.  Arranging investigations for aHUS patients in the UK 
Details of  European laboratories which are able to undertake the aforementioned 
investigations are provided by Ariceta et al (Ariceta, et al 2008). Within the UK the 
UK Genetics Testic Network (http://www.ukgtn.nhs.uk/gtn/Home) approved 
laboratory is the Northern Molecular Genetics Service in Newcastle upon Tyne.  The 
request form for this service is in the appendix.  This gives details of sample 
requirements and costs. vWF cleaving crotease (ADAMTS13) assay is available from 
the haematology department at University College, London. A copy of the request 
form is in the appendix. This again gives details of sample handling. 
 14 
Table 1. Classification of thrombotic microangiopathies adapted from (Besbas, et al 
2006) with permission. Those conditions which might be included under the heading 
of aHUS are highlighted. 
Advanced understanding of aetiology  
1.i Infection induced  
 (a) Shiga and verocytotoxin (shiga-like toxin)-producing bacteria 
 (b) Streptococcus pneumoniae  
 
1.ii Disorders of complement regulation, 
 (a) Genetic disorders of complement regulation 
 (b) Acquired disorders of complement regulation, for example anti-FH antibody 
 
1.iii ADAMTS13 abnormalities 
 (a) ADAMTS13 deficiency secondary to mutations 
 (b) Autoantibodies against ADAMTS13 
 
1.iv Defective cobalamine metabolism  
 
1.v Quinine induced  
 
Aetiology not fully understood  
2.i HIV 
2.ii Malignancy 
2.iii Drugs  
2.iv Pregnancy 
2.v Systemic lupus erythematosis and antiphospholipid antibody syndrome 
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Appendix 
  
 CPA Accredited Laboratory 
 
 
Complement genotyping request form 
 
Patient information: 
 
Surname……………………………………………………………………………… 
 
Forename…………………………………………………………………………….. 
 
Sex…………….   Date of Birth (dd/mm/yy)………..……………. 
 
Address………………………………………………………………………………. 
 
………………………………………………………………………………………… 
 
…….……………………………………ZIP or Postcode………………………….. 
 
Hospital……………………………………………………………………………….. 
 
Hospital number……………………………………………………………………… 
 
Other identifier (e.g. NHS number, social security number) 
 
…………………………………………………………………………………………. 
 
Referring Clinician (person to whom result will be sent): 
 
Name…………………………………………………………………………………. 
 
Address………………………………………………………………………….…… 
 
………………………………………………………………………………………… 
 
…….…………………………………….ZIP or Postcode….……………………… 
 
e-mail address………………………………………………………………………. 
 
To whom should the invoice be addressed (e.g. referring clinician,  
healthcare provider)? 
 
…………………………………………………………………………………..……. 
 
Clinical Information: 
(where available please include the levels of any complement components measured such as 
C3, C4, Factor I, Factor B, Factor H or if any genetic testing for aHUS has been carried out 
elsewhere. Please also include a pedigree if appropriate) 
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Disease code: 
 
Atypical haemolytic uraemic syndrome              
MPGN (membranoproliferative glomerulonephritis)           
please state which type (I, II or III) 
D+HUS (diarrhoeal associated haemolytic uraemic syndrome)       
TMApt (post transplant thrombotic microangiopathy)          
HELLP (haemolysis, elevated liver enzymes, low platelets)        
Macular degeneration                    
 
Tests required: 
Please note that payment must be received prior to testing for non-NHS patients 
(please contact Hazel.Forrest@nuth.nhs.uk for more information on payment) 
 
           Turnaround   Cost (£)    Test required 
       (working days)  (please tick) 
 
Serum complement screen  
(C3, C4, factor H, factor I)*     40       90        
 
CD46 expression by FACS*     40        35        
 
CFH gene (exons 18-23)      40     480        
 
CFH gene (exons 1-17)      40     320        
 
CFI gene (exons 1-13)    120     600        
 
CD46 gene (exons 1-13)    120     600        
 
Test for known mutation    10      150        
 
Factor H auto-antibodies (on a research basis only at present)       
 
*Serum screen and FACS analysis carried out at Immunology, RVI, Newcastle upon Tyne. 
 
Samples required: 
 
One 10 ml EDTA and one 5 ml clotted sample should be taken and each labelled with 
surname, forename and date of birth. The samples should be sent by courier (outside UK) or 
first class post (within UK) in a secure container (at ambient temperature) to:  
 
Dr Lisa Strain 
Northern Molecular Genetics Service 
Institute of Human Genetics 
The International Centre for Life 
Central Parkway 
Newcastle upon Tyne 
NE1 3BZ 
United Kingdom 
 
Date of sample (dd/mm/yyyy):………………………..……………………… 
 
Related links: 
 
aHUS mutation database: http://www.fh-hus.org/ 
Genetests: http://www.genetests.org/   Lab ID 777 
UK Genetic Testing Network: http://www.ukgtn.org/gtn/ 
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UCL HAEMATOLOGY DEPARTMENT 
HAEMOSTASIS RESEARCH UNIT 
 
 
 
 
 
 
vWF Cleaving Protease (ADAMTS13) Assay request form 
   
 Patient Name …………………………………………….  
 Hospital Number………………… Date of Sample Collection  ………………  
 Date of Birth……………………    Consultant ordering the assay………………..  
Date of last plasma infusion or exchange …………….. 
Assay required for Diagnosis/Clinical Management                     YES / NO 
NHS Patient    OR    PRIVATE Patient          (please circle) 
This patient is registered in the Rituximab Study                         YES / NO 
The patient is part of the Pneumococcal HUS Study                   YES / NO 
The patient is part of the Kings Sickle Study                                YES / NO 
 
Full address for Report: 
………………………………………………………………………… 
………………………………………………………………………………………………….. 
………………………………………………………………………………………………….. 
Institution’s Order No.:  
Name & Address for Billing (if different to above):  
 
 
We will assay ADAMTS13 by the collagen binding method or a peptide substrate 
assay, as available (and an inhibitor test if the activity is low). 
If additional types of ADAMTS13 assay are required (for which additional charges will 
be made), please telephone and discuss. 
SAMPLE REQUIREMENTS: 
· Collect 5ml citrated blood and ship immediately, to arrive within 4hr, OR:  
· Centrifuge at 2,000g for 15 min and (avoiding the buffy coat) pipette into 2-3x 0.5ml aliquots, 
freeze at –70oC and ship on dry ice (in a suitably vented container). 
Contact the Haemostasis Research Unit to arrange delivery. The sample must arrive between 
09.00-16.00 Monday-Friday (avoid public holidays!) with a copy of this form. The 
Department is closed outside these times. 
Delivery Address: Haemostasis Research Unit, Haematology Dept, University 
College London, 1st floor, 51 Chenies Mews, London WC1E 6HX 
 
Please telephone Dr Ian Mackie or other HRU staff (020 7679 6416/6421/6423) before sending 
sample to ensure that it is processed. (E-mail: i.Mackie@ucl.ac.uk) 
 
